Bank Julius Baer & Co
SPRY icon

Bank Julius Baer & Co’s ARS Pharmaceuticals SPRY Stock Holding History

Bank Julius Baer & Co’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,187
Closed -$1.23M – 871
2021
Q1 		$1.23M Buy
+28,187
New +$1.33M 0.01% 315

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank Julius Baer & Co's SPRY Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of ARS Pharmaceuticals (SPRY) in Q2 2021, closing a stake of 28,187 shares — an estimated $1.23M sold.

Bank Julius Baer & Co first reported a position in SPRY in Q1 2021 and held it in 1 quarter. The position peaked at $1.23M in Q1 2021. 76 funds tracked by Wall St. Rank hold SPRY as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining ARS Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 28,187 ARS Pharmaceuticals shares in Q2 2021, an estimated $1.23M.
  • Bank Julius Baer & Co first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's ARS Pharmaceuticals position peaked at $1.23M in Q1 2021.
  • 76 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.